OPK Insider Trading

Insider Ownership Percentage: 49.69%
Insider Buying (Last 12 Months): $4,111,852.32
Insider Selling (Last 12 Months): $23,874,134.15

OPKO Health Insider Trading History Chart

This chart shows the insider buying and selling history at OPKO Health by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$20M-$10M$0$10M$20MTotal Insider BuyingTotal Insider Selling

OPKO Health Share Price & Price History

Current Price: $1.66
Price Change: Price Decrease of -0.005 (-0.30%)
As of 04/1/2025 03:48 PM ET

This chart shows the closing price history over time for OPK up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$1.66Closing price on 03/31/25:

SEC Filings (Institutional Ownership Changes) for OPKO Health (NASDAQ:OPK)

64.63% of OPKO Health stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at OPK by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$19Mbought$19MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$50M$0$50MTotal InflowsTotal Outflows
OPKO Health logo
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
Read More on OPKO Health

Today's Range

Now: $1.66
Low: $1.64
High: $1.69

50 Day Range

MA: $1.68
Low: $1.47
High: $1.94

52 Week Range

Now: $1.66
Low: $1.15
High: $2.04

Volume

1,522,571 shs

Average Volume

4,724,094 shs

Market Capitalization

$1.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.7

Who are the company insiders with the largest holdings of OPKO Health?

OPKO Health's top insider investors include:
  1. Phillip Md Et Al Frost (CEO)
  2. Jane Ph D Hsiao (Vice Chairman)
  3. Elias A Zerhouni (Vice Chairman)
  4. Steven D Rubin (VP)
  5. Opko Health, Inc (Major Shareholder)
  6. Gary J Nabel (Insider)
  7. Richard C Pfenniger Jr (Director)
  8. Richard M Krasno (Director)
Learn More about top insider investors at OPKO Health.

Who are the major institutional investors of OPKO Health?

OPKO Health's top institutional investors include:
  1. Vanguard Group Inc. — 4.28%
  2. Geode Capital Management LLC — 1.23%
  3. Millennium Management LLC — 0.67%
  4. Wolverine Asset Management LLC — 0.00%
  5. Northern Trust Corp — 0.54%
  6. Charles Schwab Investment Management Inc. — 0.51%
Learn More about top institutional investors of OPKO Health stock.

Which institutional investors are selling OPKO Health stock?

Within the previous quarter, OPK stock was sold by these institutional investors:
  1. Invesco Ltd.
  2. Group One Trading LLC
  3. Voya Investment Management LLC
  4. Charles Schwab Investment Management Inc.
  5. Assenagon Asset Management S.A.
  6. Graham Capital Management L.P.
  7. Y.D. More Investments Ltd
  8. Renaissance Technologies LLC

Which institutional investors are buying OPKO Health stock?

Within the previous quarter, OPK stock was purchased by institutional investors including:
  1. Millennium Management LLC
  2. Lazard Asset Management LLC
  3. Altshuler Shaham Ltd
  4. Norges Bank
  5. Two Sigma Investments LP
  6. Marshall Wace LLP
  7. Nuveen Asset Management LLC
  8. Barclays PLC
During the last year, these company insiders have bought OPKO Health stock:
  1. Phillip Md Et Al Frost (CEO)
  2. Jane Ph D Hsiao (Vice Chairman)
  3. Elias A Zerhouni (Vice Chairman)
  4. Steven D Rubin (VP)
  5. Opko Health, Inc (Major Shareholder)
  6. Gary J Nabel (Insider)
  7. Richard C Pfenniger Jr (Director)
Learn More investors buying OPKO Health stock.